Skip to main content
SpringerLink
Log in
Book cover

Medical Imaging in Clinical Trials pp 277–291Cite as

Optical Coherence Tomography as a Biomarker in Clinical Trials for Ophthalmology and Neurology

  • Chapter
  • First Online:

  • 2163 Accesses

Abstract

In the past, clinical trials in neuro-ophthalmology have focused upon functional endpoints including Snellen visual acuity and visual field testing, both of which may have significant test/retest variability because of their dependence upon subject alertness and cognitive function. The introduction of optical coherence tomography (OCT) into the practice of clinical ophthalmology has now extended into clinical trials in both ophthalmology and neurology. Recent advances in the resolution and reproducibility of spectral-domain OCT have now produced algorithms that measure the structural integrity of the optic nerve and retina. OCT is in vivo histopathology and the qualitative and quantitative metrics of this painless, noninvasive, non-contact technology can now be correlated with traditional functional measurements to provide a complete longitudinal profile of the afferent visual system for clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

General Bibliography

  • Chen TC, Cense B, Miller JW, et al. Histologic correlation of in vivo optical coherence tomography images of the human retina. Am J Ophthalmol. 2006;141:1165–8.

    Article  PubMed  Google Scholar 

  • Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59:963–9.

    Article  PubMed  Google Scholar 

  • Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393–9.

    Article  PubMed  Google Scholar 

  • Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324–32.

    Article  PubMed  Google Scholar 

  • Frohman EM, Costello F, Stuve O, Calabresi P, Miller DH, Hickman SJ, Sergott RC, Conger A, Salter A, Krumwiede KH, Frohman TC, Balcer L, Zivadinov R. Modeling axonal degeneration within the anterior visual system. Implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol. 2008;65:26–35.

    Article  PubMed  Google Scholar 

  • Kerrison JB, Flynn T, Green WR. Retinal pathologic changes in multiple sclerosis. Retina. 1994;14:445–51.

    Article  CAS  PubMed  Google Scholar 

  • Kiernan DF, Mieler WF, Hariprasad SM. Spectral-domain optical coherence tomography: a comparison of modern high-resolution retinal imaging systems. Am J Ophthalmol. 2010;149:18–31.

    Article  PubMed  Google Scholar 

  • Lalezary M, Medeiros FA, Weinreb RN, et al. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. Am J Ophthalmol. 2006;142:576–82.

    Article  PubMed  Google Scholar 

  • Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd K, Trinkaus SK, Song HK, Cross AH. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009;72:1077–82.

    Article  CAS  PubMed  Google Scholar 

  • Parisi V, Manni G, Spadaro M, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40:2520–7.

    CAS  PubMed  Google Scholar 

  • Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology. 2007;69:2085–92.

    Article  CAS  PubMed  Google Scholar 

  • Sergott RC, Frohman E, Glanzman R, Al-Sabbagh A. The role of optical coherence tomography in multiple sclerosis: expert panel consensus. J Neurol Sci. 2007;263(1):3–14.

    Article  PubMed  Google Scholar 

  • Spaide RF, Curio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography. Literature review and model. Retina. 2011;31:1609–19.

    Article  PubMed  PubMed Central  Google Scholar 

  • Spain RI, Maltenfort M, Sergott RC, Leist TP. Disease duration-dependent retinal nerve fiber layer loss in untreated multiple sclerosis: the natural history of retinal axonal degeneration in multiple sclerosis. J Rehabil Res Dev. 2009;46(5):633–42.

    Article  PubMed  Google Scholar 

  • Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278–85.

    Article  CAS  PubMed  Google Scholar 

  • Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383–91.

    Article  PubMed  Google Scholar 

  • Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage. 2006;31:286–93.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

Dr. Sergott is a paid consultant for Heidelberg Engineering and for Thrombogenics.

Author information

Authors and Affiliations

  1. Department of Neuro-Ophthalmology, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA, 19107, USA

    Robert C. Sergott MD

Authors
  1. Robert C. Sergott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. Sergott MD .

Editor information

Editors and Affiliations

  1. Medical Affairs, BioClinica Inc., Newtown, Pennsylvania, USA

    Colin G. Miller

  2. Department of Strategy and Regulatory Affairs, TherapeuticsMD, Boca Raton, Florida, USA

    Joel Krasnow

  3. Dept. of Radiology, Columbia University Medical Center, New York, New York, USA

    Lawrence H. Schwartz

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Sergott, R.C. (2014). Optical Coherence Tomography as a Biomarker in Clinical Trials for Ophthalmology and Neurology. In: Miller, C., Krasnow, J., Schwartz, L. (eds) Medical Imaging in Clinical Trials. Springer, London. https://doi.org/10.1007/978-1-84882-710-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-710-3_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-709-7

  • Online ISBN: 978-1-84882-710-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation